"Researchers have been using advanced analysis, storage, and visualization capabilities from our partners to complement our mapping, genome assembly, variant calling, and annotation capabilities," explains Clifford Reid, Ph.D., chairman, president, and CEO of Complete Genomics. "We are launching this program to let the entire genetic research community know that these partners offer solutions compatible with Complete Genomics' data that can accelerate the pace of biological discoveries."

Ingenuity Variant Analysis™ is a software product focused on enabling rapid filtering and annotation of variants from human re-sequencing studies. It helps researchers prioritize among millions of variants and identify those that are most likely to be biologically significant. This tool leverages Ingenuity's Knowledge Base, a database of over 4 million findings on the connections between genomic variants and biological pathways gleaned from peer-reviewed journals, literature, and other public genomic data sources. It can reportedly identify causal variants for a rare disease, driver variants for a particular cancer, or variants associated with response or nonresponse to a therapeutic or rare adverse event.

"Accurate biological interpretation is critical to efficiently identify causal variants from DNA re-sequencing studies," states Peter van der Spek, Ph.D., Erasmus University Medical Center. Dr. van der Spek's recent work with Complete Genomics and Ingenuity Systems resulted in the identification of a novel causal variant for craniosynostosis-1 a congenital malformation of the skull.

Golden Helix' SNP and Variation Suite (SVS) is a desktop solution that combines powerful variant classification, bioinformatic filtering, functional annotation, visualization, and statistical analysis capabilities into one flexible product. By allowing customers to take control of individual steps within the analysis process, SVS empowers them to quickly uncover statistically significant genotype-phenotype associations or causal variants in large-scale data, the company notes.

DNAnexus will provide an instant genomics data and analysis center with its cloud-based solutions for customers' sequencing data. DNAnexus offers feature-rich data visualization and interpretation tools to view and filter variant, CNV, SV, and read data through a web service that requires no additional software or hardware investment.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

Be sure to take the GEN Poll

Climate Change

How would you describe the researchers response to the 2°C global temperature target?

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

45.5%

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

9.1%

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.